|
| Press Releases |
|
 |
|
| Tuesday, April 15, 2025 |
|
|
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA |
| HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic liver and metabolic diseases, today announced that two Phase 3 trials (SYMPHONY 1 and SYMPHONY 2) of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. more info >> |
|
|
熊去氧膽小檗堿（HTD1801）一藥多效 即將進入商業化新紀元 |
| 君聖泰醫藥（股票代碼: 2511.HK），一家專注于開發多功能創新療法以解決慢性肝病和代謝性疾病未滿足臨床需求的醫藥公司，今日宣佈，熊去氧膽小檗堿（HTD1801）在中國2型糖尿病（T2DM）患者中開展的兩項3期臨床試驗（SYMPHONY 1和SYMPHONY 2）達到主要療效終點及多個次要療效終點。 more info >> |
|
|
熊去氧胆小檗碱（HTD1801）一药多效 即将进入商业化新纪元 |
| 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能创新疗法以解决慢性肝病和代谢性疾病未满足临床需求的医药公司，今日宣布，熊去氧胆小檗碱（HTD1801）在中国2型糖尿病（T2DM）患者中开展的两项3期临床试验（SYMPHONY 1和SYMPHONY 2）达到主要疗效终点及多个次要疗效终点。 more info >> |
|
| Thursday, March 20, 2025 |
|
|
MASH疾病領域的大市場、大需求 |
| 代謝相關脂肪性肝炎（MASH）已成為全球醫藥行業正在挖掘的潛力「富礦」——2030年MASH市場規模將突破322億美元，患者人數超4.8億，至今FDA僅批准了一款藥物。MASH作為一種與代謝紊亂相關的肝臟疾病，表現為肝臟中脂肪異常堆積，並伴隨炎症和肝臟纖維化，可進展為肝硬化和肝細胞癌，是全球肝移植的主要病因，更顯著增加了心血管疾病的風險。 more info >> |
|
| Wednesday, March 19, 2025 |
|
|
MASH疾病领域的大市场、大需求 |
| 代谢相关脂肪性肝炎（MASH）已成为全球医药行业正在挖掘的潜力“富矿”——2030年MASH市场规模将突破322亿美元，患者人数超4.8亿，至今FDA仅批准了一款药物。 more info >> |
|
| Tuesday, March 4, 2025 |
|
|
重磅發佈 - 君聖泰醫藥在JAMA Network Open發表熊去氧膽小檗鹼治療2型糖尿病的臨床2期研究數據 療效顯著 多重代謝獲益 市場前景廣闊 |
| 中國深圳、美國馬里蘭州羅克維爾，君聖泰醫藥（股票代碼: 2511.HK），一家專注于開發多功能多靶點創新療法、解決代謝性疾病及慢性肝病未滿足臨床需求的醫藥公司，今日宣佈，熊去氧膽小檗堿（HTD1801）治療2型糖尿病（T2DM）的臨床2期研究結果在期刊JAMA Network Open發表。 more info >> |
|
|
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, today announced that data from the Phase 2 proof-of-concept study evaluating berberine ursodeoxycholate (HTD1801) for the treatment of type 2 diabetes mellitus (T2DM) was published online in JAMA Network Open. more info >> |
|
|
重磅发布 - 君圣泰医药在JAMA Network Open发表熊去氧胆小檗碱治疗2型糖尿病的临床2期研究数据 疗效显著 多重代谢获益 市场前景广阔 |
| 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能多靶点创新疗法、解决代谢性疾病及慢性肝病未满足临床需求的医药公司，今日宣布，熊去氧胆小檗碱（HTD1801）治疗2型糖尿病（T2DM）的临床2期研究结果在期刊JAMA Network Open发表。 more info >> |
|
| Thursday, February 27, 2025 |
|
|
迪拜高层代表团一行参访君圣泰医药 解码中国医药创新范式 |
| 由迪拜酋长办公室、迪拜未来基金会，迪拜市政厅及迪拜商会等十余家迪拜政商机构领袖组成的代表团抵达深圳，对中国开展创新经验交流考察，参访本地创新生态企业。 more info >> |
|
| Friday, October 25, 2024 |
|
|
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024 |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting, taking place from November 15-19, 2024 in San Diego, California. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Euro Manganese Announces Early Appointment of Chairman and Provides Financing Update
Apr 16, 2025 03:40 HKT/SGT
|
|
|
Kincora Copper: Second Major Earn-In Secured with AngloGold Ashanti
Apr 16, 2025 03:23 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates Launch of Field X Fashion, Issue 2, Brand's Award-Winning Global, Digital Magazine Celebrating Sport and Fashion
Apr 15, 2025 22:07 HKT/SGT
|
|
|
Ausnutria Delivers Resilient Dual Growth in Revenue and Profit in 2024
Apr 15, 2025 22:06 HKT/SGT
|
|
|
Bahrain Launches Informational Website and Hotline for the Golden Residency to Attract Global Professionals and Investors
Apr 15, 2025 22:06 HKT/SGT
|
|
|
TransNusa Becomes First Indonesian Airline to Launch Scheduled Bali - Guangzhou Route
Apr 15, 2025 22:05 HKT/SGT
|
|
|
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA
Apr 15, 2025 22:04 HKT/SGT
|
|
|
Standard Chartered GBA Business Confidence Survey shows calm before tariff storm in Q1
Apr 15, 2025 18:57 HKT/SGT
|
|
|
Kincora Copper: Investor Briefing Webinar - Sixth Asset Level Agreement
Apr 15, 2025 18:09 HKT/SGT
|
|
|
CTF Life Supports 10 Local Schools with Donations of Dr MAC Classroom Reading Programme and Learning Living Chinese Programme
Apr 15, 2025 17:52 HKT/SGT
|
|
|
付英波：以香港為支點 解碼百望股份全球化數據智能戰略佈局
Apr 15, 2025 14:25 HKT/SGT
|
|
|
付英波：以香港为支点 解码百望股份全球化数据智能战略布局
Apr 15, 2025 14:20 HKT/SGT
|
|
|
いすゞと富士通、商用SDVの実現に向けたパートナーシップ契約を締結
Apr 15, 2025 13:30: JST
|
|
|
三菱重工、浮体式石油・ガス生産貯蔵積出設備向けCO₂回収モジュールの初期検討を受注
Apr 15, 2025 13:30: JST
|
|
|
Isuzu and Fujitsu sign partnership agreement to commercialize software defined vehicles
Apr 15, 2025 12:29 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
